BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlySure CEO to Present Clinical Trial Updates at Fall Medtech Industry Conferences


9/25/2012 11:44:36 AM

September 25, 2012, Oxfordshire, England: GlySure Limited, developer of in-hospital continuous glucose monitoring (CGM) systems, will update the industry on its progress toward U.S. and European regulatory trials at two leading MedTech conferences this fall. GlySure CEO Christopher Jones will speak at the AdvaMed 2012 MedTech Conference on October 2 in Boston, and at the Medical Devices Summit Europe on November 14 in Dublin.

Tight Glycemic Control (TGC) in the Intensive Care Unit (ICU) has been shown to improve outcomes, reduce mortality and cut the cost of care. GlySure recently conducted human use trials that prove its system can continuously measure glucose levels across the entire human physiological range with an extremely high degree of accuracy and repeatability, which is key to effectively implementing TGC. The company is now preparing for its European and U.S. clinical regulatory trials. The Advanced Medical Technology Association (AdvaMed) has selected GlySure as one of 70 medical device companies to present at its annual conference, which is attended by nearly 2,000 global MedTech executives, policy-makers, financiers, media and industry stakeholders. At the event, Jones will present the results of GlySure’s latest clinical trials and outline the company’s plans for CE and FDA regulatory trials in the coming months.

The producers of the 2012 Medical Devices Summit Europe have chosen Jones as one of 25 key MedTech leaders to share his insights on the global medical device industry. As a CEO with experience running both U.S. and European device companies, Jones will discuss “Strategies and Lessons Learned in International Distribution”.

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: 508-314-3127. kara@kdvcommunications.com

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU). The company has demonstrated through ICU testing highly accurate sensors, which can provide continuous glucose readings throughout the length of a patient’s stay in the ICU. GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 20 employees. The company’s products are not approved for use in the U.S. or Europe. www.glysure.com



Read at BioSpace.com

GlySure
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES